Rintodestrant治疗中转移性ER阳性乳腺癌患者的18F-FES生物分布
本研究纳入8例接受选择性雌激素受体降解剂rintodestrant治疗的转移性ER阳性乳腺癌患者,于基线、治疗4-6周及治疗结束后行18F-FES PET/CT,描述示踪剂生物分布。结果显示治疗期间全血及血浆18F-FES浓度显著升高,子宫和垂体等ER表达组织摄取下降,治疗结束后趋向恢复基线;其他健康组织摄取稳定。
要点
- Rintodestrant治疗期间全血及血浆18F-FES浓度显著升高(P<0.05)。
- 子宫和垂体18F-FES摄取在治疗期间下降,治疗结束后趋向恢复基线。
- 其他健康组织摄取在三个时间点保持稳定。
核心结论
- Rintodestrant治疗会改变18F-FES在血液及ER表达健康组织中的生物分布,可能影响18F-FES摄取的解读与定量。
- 治疗结束后6天或更久,生物分布恢复至基线值,与药物洗脱后ER可用性恢复一致。
研究设计与样本
- 研究纳入8例接受rintodestrant治疗的转移性ER阳性乳腺癌患者。
- 患者在基线、治疗4-6周(中期)及治疗结束后接受18F-FES PET/CT显像。
- 静脉注射200 MBq(±10%)18F-FES后行50分钟胸部动态PET/CT,注射后60分钟行全身PET/CT。
- 采集血样测定全血与血浆放射性浓度及18F-FES母体分数。
- 在动态及全身PET上勾画升主动脉和健康组织感兴趣区,计算SUV和靶本比(TBR)以及输入函数与时间-活度曲线的曲线下面积(AUC)。
主要发现
- 全血(及血浆)18F-FES浓度在中期显著升高(P<0.05),基线、中期、治疗结束后中位AUC分别为96.6、116.6、110.3。
- 子宫在中期SUV下降50.6%、TBR下降58.5%,治疗结束后较基线SUV下降21.5%、TBR下降37.9%。
- 垂体在中期SUV下降39.0%、TBR下降48.3%,治疗结束后较基线SUV下降14.2%、TBR下降26.0%。
- 其他健康组织的示踪剂摄取在三个时间点保持稳定。
临床怎么用
- 在接受rintodestrant治疗的患者中解读18F-FES PET/CT时,需考虑治疗对血液本底及ER表达健康组织摄取的改变。
- 治疗结束后6天或更久生物分布恢复基线,提示此时显像受药物影响较小。
局限性
- 样本量较小(8例患者),结果需在更大样本中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
16α-18F-fluoro-17β-estradiol (18F-FES) is a PET tracer characterizing the expression of the estrogen receptor (ER). Because therapy can interfere with the kinetics and biodistribution of 18F-FES, the aim of this study was to describe the biodistribution of 18F-FES in patients with metastatic ER-positive (ER+) breast cancer undergoing treatment with rintodestrant (G1T48), a novel selective ER degrader. Methods: Eight patients underwent 18F-FES PET/CT imaging at baseline, 4-6 wk during treatment with rintodestrant (interim), and after treatment. After intravenous administration of 200 MBq (±10%) of 18F-FES, a 50-min dynamic PET/CT scan of the thorax was obtained, followed by a whole-body PET/CT scan 60 min after injection. Blood samples were drawn for measuring whole blood and plasma activity concentration and the parent fraction of 18F-FES. Volumes of interest were placed in the aorta ascendens and in healthy tissues on both dynamic and whole-body PET scans. SUVs and target-to-blood ratios (TBRs) were calculated. Areas under the curve (AUCs) of input functions and time-activity curves were calculated as a measure of uptake in different regions. Results:18F-FES concentration in whole blood (and plasma) significantly (P < 0.05) increased at interim with median AUCs of 96.6, 116.6, and 110.3 at baseline, interim, and after treatment, respectively. In ER-expressing tissues, that is, the uterus and the pituitary gland, both SUV and TBR showed high 18F-FES uptake at baseline, followed by a decrease in uptake at interim (uterus: SUV -50.6% and TBR -58.5%; pituitary gland: SUV -39.0% and TBR -48.3%), which tended to return to baseline values after treatment (uterus: SUV -21.5% and TBR -37.9%; pituitary gland: SUV -14.2% and TBR -26.0%, compared with baseline). In other healthy tissues, tracer uptake remained stable over the 3 time points. Conclusion: The biodistribution of 18F-FES is altered in blood and in ER-expressing healthy tissues during therapy with rintodestrant. This indicates that rintodestrant alters the kinetics of the tracer, possibly affecting interpretation and quantification of 18F-FES uptake. Of note, 6 d or more after treatment with rintodestrant ended, the biodistribution returned to baseline values, consistent with recovery of ER availability after washout of the drug.
引用
- Iqbal R, Yaqub M, Oprea-Lager DE, et al. Biodistribution of 18F-FES in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant (G1T48), a Novel Selective ER Degrader. J Nucl Med. 2021. PMID: 34446451. doi:10.2967/jnumed.121.262500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。